先天性长QT综合征患者长期使用致尖端扭转风险药物与心律失常及死亡风险
该丹麦多中心注册研究纳入279例先天性长QT综合征(cLQTS)患者,随访发现60%在诊断后使用过致尖端扭转(TdP)风险药物,且使用率随时间增加。未发现TdP风险药物与室性心律失常或全因死亡显著相关,但事件数少。
要点
- cLQTS诊断后60%患者使用过TdP风险药物,以抗生素、质子泵抑制剂、抗抑郁药和抗真菌药常见。
- 诊断后1年TdP风险药物使用率较诊断前1年下降,但5年后仍有33.5%在使用。
- 未发现TdP风险药物与室性心律失常或全因死亡显著相关,但事件数少。
核心结论
- cLQTS患者诊断后使用TdP风险药物常见且随时间增加,需提高对该高危患者群体处方模式的意识。
研究设计与样本
- 丹麦四家遗传性心脏病诊所1995-2015年确诊的cLQTS患者279例,通过全国注册数据库个体 linkage 确定TdP风险药物使用,采用Cox风险分析。
主要发现
- 随访期间167/279(60%)cLQTS患者诊断后接受过TdP风险药物治疗。
- 最常见TdP风险药物为抗生素(34.1%)、质子泵抑制剂(15.0%)、抗抑郁药(12.0%)和抗真菌药(10.2%)。
- 诊断后1年TdP风险药物治疗率较诊断前1年下降(28.4% vs 23.2%,P < 0.001),诊断后5年33.5%仍在治疗(P < 0.001)。
- TdP风险药物治疗的危险因素包括诊断年龄(每5年增量)[HR=1.07,CI 1.03-1.11]和既往TdP风险药物治疗(HR=2.57,CI 1.83-3.61)。
- 随访期间9例因室性心律失常入院(3例正在使用TdP风险药物),8例死亡(4例正在使用TdP风险药物);TdP风险药物使用与室性心律失常或全因死亡无显著关联(P=0.53和P=0.93),但事件数少。
临床怎么用
- 对cLQTS患者应加强处方审核,避免使用TdP风险药物,尤其诊断年龄较大及既往使用者。
局限性
- 室性心律失常和死亡事件数少,可能不足以检测显著关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: It is Class I recommendation that congenital long QT syndrome (cLQTS) patients should avoid drugs that can cause torsades de pointes (TdP). We determined use of TdP risk drugs after cLQTS diagnosis and associated risk of ventricular arrhythmia and all-cause mortality. METHODS AND RESULTS: Congenital long QT syndrome patients (1995-2015) were identified from four inherited cardiac disease clinics in Denmark. Individual-level linkage of nation-wide registries was performed to determine TdP risk drugs usage (www.crediblemeds.org) and associated risk of ventricular arrhythmias and all-cause mortality. Risk analyses were performed using Cox-hazards analyses. During follow-up, 167/279 (60%) cLQTS patients were treated with a TdP risk drug after diagnosis. Most common TdP risk drugs were antibiotics (34.1%), proton-pump inhibitors (15.0%), antidepressants (12.0%), and antifungals (10.2%). Treatment with a TdP risk drug decreased 1 year after diagnosis compared with 1 year before (28.4% and 23.2%, respectively, P < 0.001). Five years after diagnosis, 33.5% were in treatment (P < 0.001). Risk factors for TdP risk drug treatment were age at diagnosis (5-year increment) [hazard ratio (HR) = 1.07, confidence interval (CI) 1.03-1.11] and previous TdP risk drug treatment (HR = 2.57, CI 1.83-3.61). During follow-up, nine patients were admitted with ventricular arrhythmia (three were in treatment with a TdP risk drug). Eight patients died (four were in treatment with a TdP risk drug). No significant association between TdP risk drug use and ventricular arrhythmias or all-cause mortality was found (P = 0.53 and P = 0.93, respectively), but events were few. CONCLUSION: Torsades de pointes risk drug usage was common among cLQTS patients after time of diagnosis and increased over time. A critical need for more awareness in prescribing patterns for this high-risk patient group is needed.
引用
- Weeke PE, Kellemann JS, Jespersen CB, et al. Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality. Eur Heart J. 2019. PMID: 31079148. doi:10.1093/eurheartj/ehz228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。